secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070298
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports $20.5M cash; strategic alternatives review ongoing
---------------------------------------------------------------------

- Cash and cash equivalents $20.5M as of March 31, 2025, with no outstanding debt.
- Strategic alternatives review continues since July 2024; Oppenheimer & Co. serving as exclusive financial advisor.
- Reduction-in-force progressing in stages as operational and strategic direction evolves.
- No assurance any transaction will result; updates only if completed or legally required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017025070298/0000950170-25-070298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017025070298/meip-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer